The SCOPA–Motor Scale for assessment of Parkinson's disease is a consistent and valid measure

Martinez‐Martín, Pablo; Benito‐León, Julián; Burguera, J.A.; Castro, Alfonso; Linazasoro, Gurutz; Martínez‐Castrillo, Juan Carlos; Valldeoriola, Francesc; Vázquez, Antonio; Vivancos, Francisco; Val, Javier del; Blercom, Nadèje van; Frades, Belén

doi:10.1016/j.jclinepi.2004.09.014

Cited by 82 publications

(66 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(A) Motor impairment was assessed with the Short Parkinson's Evaluation Scale / Scales for Outcomes in Parkinson's disease (SPES/SCOPA) motor examination which has been shown to highly correlate with the MDS-UPDRS motor examination 18 . Motor complications and ADL were also assessed with the SPES/SCOPA scale which correlates with corresponding parts of the UPDRS scale 19 .…”

Section: Clinical Assessmentmentioning

confidence: 99%

Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease

et al. 2016

View full text Add to dashboard Cite

BACKGROUND STN-DBS is well established to improve motor symptoms and quality of life in patients with PD. While non-motor symptoms are crucial for quality of life in these patients, only neuropsychiatric and neuropsychological symptoms have been systematically studied in a longitudinal design thus far. However, these are only a part of the spectrum of non-motor symptoms in PD. We hypothesized that STN-DBS is associated with a beneficial effect on a range of non-motor symptoms. METHODSIn this multicenter, open, prospective, international study we investigated non-motor effects of STN-DBS in "real-life" use. We evaluated Non-motor Symptom Scale, and Questionnaire, PD Questionnaire-8, Scales for Outcomes of PD motor examination and complications, and activities of daily living preoperatively and at 6 months follow-up in 60 consecutive patients (35 male, mean age: 61.64 ±7.84 years, mean disease duration: 10.45 ±4.22 years) undergoing STN-DBS. RESULTSAll outcomes improved significantly at 6 months follow-up (PD Questionaire-8, p=0.006; activities of daily living, p=0.012; all others, p<0.001; Wilcoxon signedrank, respectively paired t-test; Bonferroni-correction). Post-hoc analyses of Nonmotor Symptom Scale domains showed a significant reduction of sleep/fatigue and miscellaneous domains (p≤0.001), perceptual problems/hallucinations (p=0.036), and urinary (p=0.018) scores. Effect sizes were "moderate" effect for Non-motor Non-motor effects of subthalamic DBS -5 -Symptom Scale, and motor complications, "large" for motor examination, and "small" for other outcomes. CONCLUSIONSThis study provides first evidence that bilateral STN-DBS improves non-motor burden in patients with PD and opens the door to a more balanced evaluation of DBS outcomes. Further randomized studies are needed to confirm these findings and compare DBS non-motor effects to other therapies such as infusion based treatments of advanced PD.

show abstract

Section: Clinical Assessmentmentioning

confidence: 99%

Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The SCOPA-Motor Scale can be completed in approximately half the time of the UPDRS, and has been shown to be a consistent and valid measure of motor function, disability, and complications of therapy. 15 The SCOPA-Motor requires a clinical exam by a trained provider and does not address common and debilitating non-motor symptoms, limiting its utility as a single outcome measure for the comprehensive assessment of PD. The Self-Assessment PD Disability Scale assesses disability in nine daily activities and is targeted toward patients living at home.…”

Section: Introductionmentioning

confidence: 99%

Use of a self-rating scale of the nature and severity of symptoms in Parkinson’s Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity

Mischley

Lau

Weiss

2017

npj Parkinson's Disease

View full text Add to dashboard Cite

A self-rating scale was developed to permit patient-reported, remote assessment of Parkinson’s disease symptom severity. The goal was to create a continuous outcome measure that does not require a clinical exam, does not fluctuate in response to dopaminergic medications, takes only a few minutes to complete, allows for stratification by symptom(s), and captures both motor and non-motor Parkinson’s disease symptoms, major contributors to quality of life. The Patient Reported Outcomes in Parkinson’s Disease (PRO-PD) is the cumulative score of 32 slider bars, each evaluating a common Parkinson’s disease symptom. The PRO-PD has been used as an outcome measure in three studies. The baseline data from each of these studies were pooled for this analysis. Symptom frequency and severity are described, as well as correlation coefficients with existing measures of Parkinson's disease severity. Data on 1031 participants with Parkinson's disease were available for analysis. Fatigue, impaired handwriting, daytime sleepiness, slowness, tremor, muscle cramps, and forgetfulness were the most frequently reported symptoms. Persons with a relatively long duration of Parkinson's disease tended to report more, and more severe, symptoms. The PRO-PD was most highly correlated with the Parkinson’s Disease Questionaire-39 (r = 0.763, P < 0.000) and Patient-Reported Outcome Measurement Information System Global quality of life (r = −0.7293, P < 0.000), other patient-reported quality of life measures. The PRO-PDnon-motor subset was highly correlated with the Non-Motor Symptom Score (r = 0.7533, P < 0.000). There was a moderate correlation seen with Hoehn & Yahr (r = 0.5922, P < 0.000), total Unified Parkinson’s disease Rating Scale (r = 0.4724, P < 0.000), and the Timed-Up-&-Go (r = 0.4709, P < 0.000). The PRO-PD may have utility for patients, providers, and researchers as a patient-centered measure of Parkinson’s disease symptom severity. Further PRO-PD validation efforts are warranted.

show abstract

“…Frontal assesment battery 10.8 (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17) degeneration in vagal nerve, spinal cord and celiac ganglion. This explained the clinical variety in motor and non-motor findings 13 .…”

Section: Resultsmentioning

confidence: 99%

“…18 . Clinical presence and severity of autonomous involvement in PD is assessed effectively and correctly by using SCOPA-AUT questionnaire 8 . SCOPA-AUT study showed association between the degree of motor exposure in PD and autonomous symptoms.…”

Section: Resultsmentioning

confidence: 99%

Effect of clinical autonomic dysfunction on cognitive functions in Parkinson’s disease

Aygün¹,

Akpınar²,

Yön³

et al. 2017

Dicle Tıp Dergisi

View full text Add to dashboard Cite

Objective: Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder characterized by tremor, rigidity, bradykinesia, and postural instability. PD also involves nonmotor manifestations such as autonomic failure, cognitive disorders, and sleep disorders. These clinical characteristics are not identical in severity, frequency, and onset time in all PD patients. We assessed whether there is a negative effect on cognition of clinical autonomic dysfunction in PD patients.Results: Mean age was 66,5±11.2 years. There was no correlation between cognitive test scores and SCOPA-OUT scores (p>0.05). However, H-Y scores were negatively correlated with the DSTf, DSTr, FAB, and MMSE scores (p50.005, r:-0.451; p50.025, r: -0.367; p50.040, r: -0.340; p50.044, r5-0.333, respectively). Training and Education Hospital, Neurology clinic, Samsun, Turkey e-mail: dr_ckakpinar@hotmail.com Original Article/Özgün Araştırma Conclusions: According to our results, clinical autonomic dysfunction did not seem to have an effect on cognition. In addition, severity of cognitive dysfunction showed a strong negative correlation with the stage of disease.

show abstract

The SCOPA–Motor Scale for assessment of Parkinson's disease is a consistent and valid measure

Cited by 82 publications

References 28 publications

Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease

Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease

Use of a self-rating scale of the nature and severity of symptoms in Parkinson’s Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity

Effect of clinical autonomic dysfunction on cognitive functions in Parkinson’s disease

Contact Info

Product

Resources

About